Table 2.
Group tested | CXCL12 (ng/mL) |
CXCR4 (ng/mL) |
CEA (ng/mL) |
SCC-Ag (ng/mL) |
CRP (ng/mL) |
|
---|---|---|---|---|---|---|
Control group (n = 30) | Median (range) |
0.865
(0.105–4.297) |
0.932
(0.079–2.879) |
1.230
(0.500–4.540) |
1.000
(0.600–2.500) |
1.050
(0.200–10.900) |
| ||||||
Esophageal cancer (n = 49) Total group |
Median (range) p (EC versus healthy controls) |
1.277
(0.108–3.106) 0.044∗ |
0.443
(0.049–1.516) 0.031∗ |
2.220
(0.500–65.060) 0.003∗ |
1.200
(0.400–8.100) 0.567 |
6.500
(0.200–217.600) <0.001∗ |
| ||||||
Adenocarcinoma of esophagus (AC) (n = 24) | Median (range) p (AC versus healthy controls) |
1.118
(0.108–2.697) 0.216 |
0.403
(0.049–1.516) 0.026∗ |
1.955
(0.500–46.550) 0.034∗ |
0.800
(0.400–2.200) 0.154 |
2.800
(0.200–46.800) 0.031∗ |
| ||||||
Squamous cell cancer of esophagus (ESCC) (n = 25) | Median (range) p (ESCC versus healthy controls) p (AC versus ESCC) |
1.501
(0.380–3.106) 0.030∗ 0.562 |
0.534
(0.076–1.466) 0.146 0.168 |
2.250
(0.500–65.060) 0.013∗ 0.904 |
1.400
(0.500–8.100) 0.006∗ 0.003∗ |
14.900
(0.200–217.600) <0.001∗ 0.008∗ |
∗Statistically significant when p < 0.05.